LONDON, February 2, 2012 /PRNewswire/ --
AstraZeneca, the Anglo-Swedish pharmaceutical company, said that government price intervention had reduced its revenues by about $1bn as it announced further restructuring alongside its full-year results.
In an interview on http://www.cantos.com, David Brennan, CEO, discusses AstraZeneca’s portfolio performance including Brilinta and Crestor, and the prospects for the pipeline in light of recent disappointments.
He also reaffirms his strong commitment to returning cash to shareholders.
Also interviewed about the rationale behind the latest phase of the restructuring, Martin Mackay, President, R&D, said:
“We have to be a very flexible organisation to make sure that we’re dynamic enough to work in the environment that we work in but also produce great medicines.”
Tony Zook, EVP, Global Commercial, also talks about his confidence in AstraZeneca’s ability to deliver top line performance and the importance of emerging markets for future growth.
MerchantCantos produces in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email prnsupport@merchantcantos.com or phone +44-207-936-1352.
SOURCE AstraZeneca
